Patents Assigned to The Wistar Institute of Anatomy and Biology
-
Publication number: 20140274794Abstract: Methods and compositions are provided for diagnosing ovarian cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of ovarian cancer, or the identification of a risk of developing ovarian cancer, or enables the monitoring of the status of progression or remission of ovarian cancer in the subject followed during a therapeutic protocol.Type: ApplicationFiled: September 7, 2012Publication date: September 18, 2014Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: David W. Speicher, Hsin-Yao Tang, Lynn A. Beer
-
Publication number: 20140272947Abstract: A high-throughput method for identifying a compound or biomolecule that modulates cell senescence involves simultaneously measuring in a cell population exposed to the test compound or biomolecule, the expression of a senescence marker and cell number, wherein each well contains a single test compound; and determining from said simultaneous measurements whether the test compound increases or decreases cell senescence. In various embodiments, the method is useful is identifying compounds that delay the aging process of normal healthy cells, or identifying a compound useful as a tumor suppressor or identifying a compound useful in the treatment of cancer.Type: ApplicationFiled: March 10, 2014Publication date: September 18, 2014Applicants: Fox Chase Cancer Center, The Wistar Institute of Anatomy and BiologyInventors: Rugang Zhang, Benjamin Guy Bitler, Jeffrey Peterson
-
Publication number: 20140256586Abstract: Methods and compositions are provided for diagnosing colorectal cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of colorectal cancer, or the identification of a risk of developing colorectal cancer, or enables the monitoring of the status of progression or remission of colorectal cancer in the subject followed during a therapeutic protocol.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: The Wistar Institute of Anatomy and BiologyInventors: David W. Speicher, Wona Joo
-
Publication number: 20140241983Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.Type: ApplicationFiled: October 24, 2012Publication date: August 28, 2014Applicant: The Wistar Institute of Anatomy and BiologyInventors: Hui Hu, Jose R. Conejo-Garcia, Tom-Li Stephen
-
Publication number: 20140121127Abstract: Methods and compositions are provided for diagnosing ovarian cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of ovarian cancer, or the identification of a risk of developing ovarian cancer, or enables the monitoring of the status of progression or remission of ovarian cancer in the subject followed during a therapeutic protocol.Type: ApplicationFiled: October 29, 2013Publication date: May 1, 2014Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Publication number: 20140099340Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.Type: ApplicationFiled: September 30, 2013Publication date: April 10, 2014Applicants: The Wistar Institute of Anatomy and Biology, The Trustees of the University of PennsylvaniaInventors: Carl H. June, Ellen Pure, Liang-Chuan Wang, Steven Albelda, John Scholler
-
Publication number: 20140100130Abstract: A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g.Type: ApplicationFiled: October 3, 2013Publication date: April 10, 2014Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Patent number: 8476420Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile.Type: GrantFiled: December 5, 2008Date of Patent: July 2, 2013Assignees: The Wistar Institute of Anatomy and Biology, The Trustees of the University of PennsylvaniaInventors: Michael Showe, Louise Showe, Malik Yousef, Steven M. Albelda, Anil Vachani, Andrei V. Kossenkov
-
Publication number: 20130028924Abstract: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.Type: ApplicationFiled: September 22, 2011Publication date: January 31, 2013Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: Hildegund C.J. ERTL, Marcio O. LASARO
-
Patent number: 8106039Abstract: Provided are novel organometallic compounds that inhibit PI3K lipid kinase and phospho-AKT in human melanoma cells, and also inhibit the migration of melanoma cells. The present invention is also directed to methods for inhibiting cancer cell proliferation, migration or both comprising contacting a cancer cell with a disclosed organometallic kinase inhibitor. Also disclosed are methods for treating a kinase-affected disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a disclosed organometallic kinase inhibitor.Type: GrantFiled: April 30, 2008Date of Patent: January 31, 2012Assignees: The Trustees Of The University Of Pennsylvania, The Wistar Institute Of Anatomy And BiologyInventors: Eric Meggers, Peng Xie, Douglas S. Williams, Ronen Marmorstein
-
Patent number: 7811993Abstract: Novel BRAFV600E mutant peptides or a pharmaceutically acceptable salt thereof, that induce MHC Class I-dependent cytotoxic T cell responses in mammals are useful in prophylactic, diagnostic and therapeutic treatments for melanoma. Such compounds are also useful in drug development for non-peptide mimics of the compounds described herein and in the development of therapeutic or diagnostic antibodies.Type: GrantFiled: June 28, 2006Date of Patent: October 12, 2010Assignee: The Wistar Institute of Anatomy and BiologyInventors: Dorothee Herlyn, Rajasekaran Somasundaram, Laszlo Otvos, Jr.
-
Publication number: 20100255486Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile.Type: ApplicationFiled: December 5, 2008Publication date: October 7, 2010Applicants: The Wistar Institute of Anatomy and Biology, The Trustees of the University of PennsylvaniaInventors: Michael Showe, Louise Showe, Malik Yousef, Steven M. Albelda, Anil Vachani, Andrei V. Kossenkov
-
Patent number: 7640114Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.Type: GrantFiled: May 21, 2004Date of Patent: December 29, 2009Assignee: The Wistar Institute of Anatomy & BiologyInventors: Louise C. Showe, Michael K. Showe, Laszlo Kari, Michael Nebozhyn, Andrey Loboda
-
Publication number: 20070178044Abstract: A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is indicative of DNA damage and the presence of diffuse signal is indicative of a normal sample. Diagnostic reagents contain a ligand that binds to human 53Bp1 associated with a detectable label. Diagnostic kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. Compositions that inhibit or antagonize the biological activity of 53Bp1 are identified by suitable assays, and are employed in methods of retarding the growth of a cancer cell.Type: ApplicationFiled: April 3, 2007Publication date: August 2, 2007Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: Thanos Halazonetis, Linda Schultz
-
Patent number: 7217532Abstract: A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is indicative of DNA damage and the presence of diffuse signal is indicative of a normal sample. Diagnostic reagents contain a ligand that binds to human 53Bp1 associated with a detectable label. Diagnostic kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. Compositions that inhibit or antagonize the biological activity of 53Bp1 are identified by suitable assays, and are employed in methods of retarding the growth of a cancer cell.Type: GrantFiled: May 30, 2001Date of Patent: May 15, 2007Assignee: The Wistar Institute of Anatomy and BiologyInventors: Thanos Halazonetis, Linda B. Schultz
-
Patent number: 7217570Abstract: An organotypic culture comprises an artificial stroma overlayed with epithelial cells isolated from a human colon or intestine. The stroma comprises a mixture of collagen and human fibroblasts isolated from a human colon or intestine. The culture contains a factor that binds the IGF-1 receptor, a factor that binds the EGF receptor, and a factor that binds the LIF receptor. These factors may be added exogenously to the culture via medium or may be expressed by various recombinantly engineered cell types in the culture. The organotypic culture can result in growth that is in situ-like or emphasizes other physiological or morphological states, depending on the balance of factors in the growth media. The organotypic culture may be used in methods for screening of therapeutic, carcinogenic, or growth enhancement factors, or for treating intestinal injuries by applying to the site of an injury the intact culture or the components thereof.Type: GrantFiled: August 22, 2002Date of Patent: May 15, 2007Assignee: The Wistar Institute of Anatomy and BiologyInventors: Meenhard Herlyn, Jiri Kalabis
-
Patent number: 7176293Abstract: An isolated nucleic acid sequence of a mitotic checkpoint gene, chfr, encodes a Chfr protein having a Forkhead-associated domain and a Ring Finger. This protein is required for regulation of the transition of cells from prophase to metaphase during mitosis. The chfr nucleic acid and Chfr polypeptide are useful in diagnosing tumorigenic cells and in screening for drugs which can inhibit the activity of Chfr in a cancer cell, thereby rendering the cell more sensitive to additional anti-tumor therapies.Type: GrantFiled: June 14, 2000Date of Patent: February 13, 2007Assignee: The Wistar Institute of Anatomy and BiologyInventors: Thanos Halazonetis, Daniel Scolnick
-
Patent number: 7150968Abstract: The present invention provides Bin2 sequences and proteins encoded thereby. Also provided are compositions and methods utilizing these sequences and proteins in the diagnosis and treatment of blood disorders, including hepatocarcinoma. Further provided are oligonucleotides derived from sequences encoding Bin2, as well as compositions and methods utilizing same for diagnostic and therapeutic purposes.Type: GrantFiled: October 29, 2004Date of Patent: December 19, 2006Assignee: The Wistar Institute of Anatomy and BiologyInventors: George C. Prendergast, Kai Ge
-
Publication number: 20060271309Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.Type: ApplicationFiled: May 21, 2004Publication date: November 30, 2006Applicant: The Wistar Institute of Anatomy and BiologyInventors: Louise Showe, Michael Showe, Laszlo Kari, Michael Nebozhyn, Andrey Loboda
-
Publication number: 20060240494Abstract: A method for identifying a compound that has a biocidal effect against a selected organism involves screening from among known or unknown peptide or non-peptide molecules, a test molecule that binds selectively to a target sequence of a multi-helical lid of a heat shock protein of the organism. The binding of the test compound inhibits the protein folding activity of the protein. A specific embodiment of such a method is useful for identifying or designing a pharmaceutical or veterinary biocidal or antibiotic compound, preferably a pathogen and/or strain-specific compound. For this purpose, the compound does not bind to a heat shock protein that is homologous to the mammalian subject to be treated with the compound. Screening methods can encompass direct binding or competitive assays. Molecules or compounds identified by these methods are employed as biocides for pharmaceutical, veterinary, pesticide, insecticide and rodenticide uses, among others.Type: ApplicationFiled: June 28, 2006Publication date: October 26, 2006Applicants: The Wistar Institute of Anatomy and Biology, Creighton UniversityInventors: Laszlo Otvos, Magdalena Blaszczyk-Thurin, Mark Rogers, Sandor Lovas